There are 2789 resources available
1435TiP - Adjuvant immunotherapy for resected esophageal squamous cell carcinoma with high risk of recurrence (AIRES): A multicenter, open-label, randomized, controlled phase III trial
Presenter: Xiaozheng Kang
Session: ePoster Display
1436TiP - Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen (DESTINY-gastric04, DG-04): A randomized phase III study
Presenter: Kohei Shitara
Session: ePoster Display
1438TiP - INTEGRATE IIb: A randomised phase III open label study of regorafenib + nivolumab vs standard chemotherapy in refractory advanced gastro-oesophageal cancer (AGOC)
Presenter: Nick Pavlakis
Session: ePoster Display
1243P - Cumulative incidence and metastatic patterns of relapsed vs de novo stage IV non-small cell lung cancer (NSCLC) characterized by histology and EGFR status
Presenter: Evan Strom
Session: ePoster Display
1244P - Real-world EGFR and T790M testing patterns in patients from Central Eastern Europe with advanced non-small cell lung cancer: Results from a large retrospective study (REFLECT)
Presenter: Mircea Dediu
Session: ePoster Display
1245P - Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance
Presenter: Ruifen Tian
Session: ePoster Display
1246P - A phase I dose-escalation study of mobocertinib (TAK-788), an oral tyrosine kinase inhibitor (TKI), in Japanese NSCLC patients
Presenter: Toyoaki Hida
Session: ePoster Display